A Neonatal Monkey Model for Tuberculosis Vaccination

结核病疫苗接种的新生猴模型

基本信息

项目摘要

ABSTRACT Tuberculosis due to Mycobacterium tuberculosis (MTB) is the leading cause of mortality due to infections today with more than 2 million deaths worldwide. BCG vaccine derived from Mycobacterium bovis is the only approved human vaccine although, it has a partial efficacy against childhood and adult tuberculosis. Since BCG lacks certain genes of wild type M. tuberculosis many recombinant BCG vaccine strains have been prepared and evaluated in animal models. Based on the observation that human neonates respond better to vaccine antigens when stimulated with Toll-like receptor (TLR) adjuvants, we constructed a novel recombinant BCG vaccine that expresses a peptide stimulating TLR-2 (TLR-BCG). This vaccine protected mice better than wild type BCG vaccine. We also developed a novel neonatal monkey model to evaluate vaccine effects against tuberculosis. This project will verify the hypothesis that, TLR-BCG vaccine will be more efficient than wild type BCG vaccine in generating stronger and longer lasting immune responses against tuberculosis in NHPs. Specific Aim-1A: We will evaluate TH1 immune responses induced by wild type BCG and recombinant TLR-BCG in the neonatal monkey model. We will determine if TLR-BCG induces qualitatively different primary T cell immune responses in NHPs compared with a natural infection with M. tuberculosis and correlate vaccine-induced protection against aerosol induced tuberculosis in NHPs. Specific Aim -2: We will evaluate long-term efficacy of TLR-BCG vaccines using a prime boost strategy with the neonatal monkey model. These studies are likely to lead to generate a better primary vaccine against tuberculosis, and a more efficient better booster vaccine for children already vaccinated with wt-BCG.
摘要 由结核分枝杆菌(MTB)引起的结核病是由于以下原因导致死亡的主要原因: 目前,全世界有超过200万人死亡。卡介苗来源于 牛分枝杆菌是唯一被批准的人类疫苗,尽管它对 儿童和成人结核病。由于BCG缺乏野生型M.结核病很多 已经制备了重组BCG疫苗株并在动物模型中进行了评价。基于 观察到当用Toll样刺激时,人类新生儿对疫苗抗原的应答更好 受体(TLR)佐剂,我们构建了一种新的重组BCG疫苗, 肽刺激TLR-2(TLR-BCG)。这种疫苗比野生型BCG更能保护小鼠 疫苗我们还开发了一种新的新生猴模型,以评估疫苗对 结核本项目将验证TLR-BCG疫苗更有效的假设 与野生型BCG疫苗相比, NHP中的结核病。具体目标-1A:我们将评估野生型抗病毒药物诱导的TH 1免疫应答。 型BCG和重组TLR-BCG在新生猴模型中的作用。我们将确定TLR-BCG 与自然免疫相比, 杆菌感染结核病和相关疫苗诱导的对气溶胶诱导的 NHP中的结核病。具体目标-2:我们将评估TLR-BCG疫苗的长期有效性 使用新生猴模型的初免加强策略。这些研究可能会导致 生产出更好的结核病初级疫苗和更有效的加强疫苗 对于已经接种过卡介苗的儿童。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Marie-Claire Elisabeth Gauduin其他文献

Marie-Claire Elisabeth Gauduin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Marie-Claire Elisabeth Gauduin', 18)}}的其他基金

Durable HIV Vaccine Targeting Mucosal Epithelium
针对粘膜上皮的耐用 HIV 疫苗
  • 批准号:
    10548066
  • 财政年份:
    2022
  • 资助金额:
    $ 90.37万
  • 项目类别:
Durable HIV Vaccine Targeting Mucosal Epithelium
针对粘膜上皮的耐用 HIV 疫苗
  • 批准号:
    10675701
  • 财政年份:
    2022
  • 资助金额:
    $ 90.37万
  • 项目类别:
A Neonatal Monkey Model of Tuberculosis Vaccination
新生猴结核病疫苗接种模型
  • 批准号:
    9901954
  • 财政年份:
    2019
  • 资助金额:
    $ 90.37万
  • 项目类别:
Recombinant Papillomavirus-based HIV Vaccine Targeting Genital Mucosa
针对生殖器粘膜的基于重组乳头瘤病毒的 HIV 疫苗
  • 批准号:
    8993591
  • 财政年份:
    2015
  • 资助金额:
    $ 90.37万
  • 项目类别:
Trans-complementing papillioma virus for AIDS vaccine
用于艾滋病疫苗的反式互补乳头状瘤病毒
  • 批准号:
    9011505
  • 财政年份:
    2015
  • 资助金额:
    $ 90.37万
  • 项目类别:
TB INFECTION IN NHP MODEL OF PEDIATRIC AIDS
NHP 儿科艾滋病模型中的结核感染
  • 批准号:
    8357722
  • 财政年份:
    2011
  • 资助金额:
    $ 90.37万
  • 项目类别:
EFFICACY OF A DNA/MVA VACCINE TO PROTECT AGAINST REPEATED VAGINAL SIV CHALLENGE
DNA/MVA 疫苗预防反复阴道 SIV 攻击的功效
  • 批准号:
    8357926
  • 财政年份:
    2011
  • 资助金额:
    $ 90.37万
  • 项目类别:
EPITHELIAL CELLS AS MUCOSAL ADJUVANT FOR LIFE LONG IMMUNITY
上皮细胞作为终身免疫的粘膜佐剂
  • 批准号:
    8357687
  • 财政年份:
    2011
  • 资助金额:
    $ 90.37万
  • 项目类别:
T-CELL FUNCTION IN PEDIATRIC AIDS
T 细胞在儿科艾滋病中的功能
  • 批准号:
    8357661
  • 财政年份:
    2011
  • 资助金额:
    $ 90.37万
  • 项目类别:
EARLY MECHANISMS OF HIV TRANSMISSION USING THE SIV/MACAQUE MODEL FOR AIDS
使用艾滋病病毒/猕猴模型研究艾滋病毒传播的早期机制
  • 批准号:
    8357670
  • 财政年份:
    2011
  • 资助金额:
    $ 90.37万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 90.37万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 90.37万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 90.37万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 90.37万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 90.37万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 90.37万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 90.37万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 90.37万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 90.37万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 90.37万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了